We are live on
!
Find out more
AA
AlphaMark Advisors Portfolio holdings
AUM
$231M
1-Year Est. Return
19.98%
This Fund
S&P 500
This Quarter
Est. Return
+6.81%
1 Year Est. Return
+19.98%
3 Year Est. Return
+26.38%
5 Year Est. Return
+72.27%
10 Year Est. Return
+180.76%
AUM
$239M
AUM Growth
+$8.32M
(+3.6%)
Cap. Flow
-$5.16M
Cap. Flow
% of AUM
-2.16%
Top 10 Holdings %
Top 10 Hldgs %
35.11%
Holding
546
New
36
Increased
93
Reduced
108
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$3.15M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$2.48M |
| 3 |
Dollar Tree
DLTR
|
+$1.94M |
| 4 |
Vanguard Morningstar Value ETF
VTV
|
+$857K |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$833K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$4.4M |
| 2 |
EOG Resources
EOG
|
+$2.91M |
| 3 |
United Therapeutics
UTHR
|
+$2.5M |
| 4 |
Zebra Technologies
ZBRA
|
+$1.98M |
| 5 |
PVH
PVH
|
+$1.43M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 10.55% |
| 2 | Consumer Staples | 7.28% |
| 3 | Technology | 6.91% |
| 4 | Consumer Discretionary | 6.75% |
| 5 | Industrials | 6.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
26
DELISTED
Alexion Pharmaceuticals
ALXN
| $3.19M | 1.33% |
+29,481
| New | +$3.15M |
|
27
Regeneron Pharmaceuticals
REGN
$78.5B
| $3.03M | 1.27% |
8,081
-929
| -10% | -$313K |
|
28
Celanese
CE
$4.9B
| $3.03M | 1.27% |
24,595
-836
| -3% | -$103K |
|
29
Thermo Fisher Scientific
TMO
$213B
| $3.02M | 1.26% |
9,300
+128
| +1% | +$38.8K |
|
30
General Dynamics
GD
$104B
| $2.97M | 1.24% |
16,867
-191
| -1% | -$34.3K |
|
|
WCG
31
DELISTED
Wellcare Health Plans, Inc.
WCG
| $2.97M | 1.24% |
8,989
-95
| -1% | -$28.5K |
|
32
Leidos
LDOS
$14.5B
| $2.87M | 1.2% |
29,286
+760
| +3% | +$67K |
|
33
Alphabet (Google) Class C
GOOG
$4.36T
| $2.85M | 1.19% |
42,640
+400
| +0.9% | +$25.8K |
|
|
34
Bristol-Myers Squibb
BMY
$133B
| $2.8M | 1.17% |
43,639
+43,389
| +17,356% | +$2.48M |
|
35
US Bancorp
USB
$98.2B
| $2.8M | 1.17% |
47,178
-1,034
| -2% | -$59.8K |
|
|
IBDO
36
DELISTED
iShares iBonds Dec 2023 Term Corporate ETF
IBDO
| $2.73M | 1.14% |
107,015
+12,060
| +13% | +$308K |
|
|
37
Dollar Tree
DLTR
$24.4B
| $2.7M | 1.13% |
28,746
+18,447
| +179% | +$1.94M |
|
38
iShares TIPS Bond ETF
TIP
$14.5B
| $2.6M | 1.09% |
22,297
-1,225
| -5% | -$142K |
|
39
Eastman Chemical
EMN
$8B
| $2.31M | 0.97% |
29,192
+236
| +0.8% | +$18.1K |
|
40
Arista Networks
ANET
$227B
| $2.3M | 0.96% |
180,608
| – | – |
|
41
PIMCO Enhanced Short Maturity Active Exchange-Traded Fund
MINT
$16.9B
| $2.27M | 0.95% |
22,295
+3,125
| +16% | +$318K |
|
|
42
Zebra Technologies
ZBRA
$14B
| $2.11M | 0.88% |
8,261
-8,443
| -51% | -$1.98M |
|
43
Nokia
NOK
$51B
| $2.09M | 0.87% |
563,259
-17,867
| -3% | -$70.3K |
|
|
44
PVH
PVH
$4B
| $1.71M | 0.71% |
16,223
-15,008
| -48% | -$1.43M |
|
45
iShares US Technology ETF
IYW
$23.6B
| $1.65M | 0.69% |
28,336
+8,380
| +42% | +$456K |
|
46
Kroger
KR
$35.4B
| $1.57M | 0.66% |
54,320
+3,513
| +7% | +$93.1K |
|
|
IBDL
47
DELISTED
iShares iBonds Dec 2020 Term Corporate ETF
IBDL
| $1.22M | 0.51% |
48,223
-2,297
| -5% | -$58.2K |
|
48
iShares MSCI EAFE Small-Cap ETF
SCZ
$13.4B
| $1.18M | 0.49% |
18,900
-1,050
| -5% | -$63.1K |
|
49
Welltower
WELL
$169B
| $999K | 0.42% |
12,210
| – | – |
|
|
IBDM
50
DELISTED
iShares iBonds Dec 2021 Term Corporate ETF
IBDM
| $932K | 0.39% |
37,325
-2,403
| -6% | -$60K |
|
Similar funds
AJ
MWS
LHR
HPFG
GWM
KC
SL
CSWM
AlphaMark Advisors's Q4 2019 Portfolio in Review
As of Q4 2019, AlphaMark Advisors held 546 positions worth $239M, up 3.6% from $231M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
AlphaMark Advisors's Q4 2019 filing shows 36 new, 93 increased, 108 reduced and 33 closed positions. Its largest new stake was Alexion Pharmaceuticals: 29,481 shares worth $3.19M. The largest sale was Celgene Corp, an estimated $4.4M.
By sector, the portfolio is most concentrated in Financials at 11% of assets, up from 10% a quarter earlier, followed by Consumer Staples and Technology.
- AlphaMark Advisors's largest Q4 2019 buy was Alexion Pharmaceuticals: 29,481 shares worth $3.19M.
- AlphaMark Advisors added most to Bristol-Myers Squibb in Q4 2019, an estimated $2.48M increase.
- AlphaMark Advisors's biggest Q4 2019 reduction was EOG Resources, cutting an estimated $2.91M.
- AlphaMark Advisors fully exited Celgene Corp in Q4 2019, selling an estimated $4.4M.
- AlphaMark Advisors's ten largest holdings make up 35% of its $239M portfolio in Q4 2019.
- AlphaMark Advisors opened 36 new positions and closed 33 in Q4 2019.
- AlphaMark Advisors's portfolio value rose 3.6% quarter-over-quarter to $239M.
Based on AlphaMark Advisors's 13F filing for Q4 2019, filed 7 Feb 2020.